Showing all 3 results
Letrozole tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of the micro-dosed endocrine disruptor.
Active Ingredient Strength Primary Clinical Function Letrozole USP/Ph.Eur. 2.5 mg Global Oncology & Fertility Standard: The universal therapeutic unit utilized for 5-to-10 year daily adjuvant breast cancer therapy, or short 5-day cyclic dosing for ovulation induction. Excipients Lactose Monohydrate / Microcrystalline Cellulose / Sodium Starch Glycolate / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry Film Diluent / Binder / Superdisintegrant / Glidant / Slipper-Coating (Engineered specifically using elite geometric dilution to ensure the microscopic 2.5mg active payload is flawlessly distributed throughout the tablet, guaranteeing absolute content uniformity) *Pack Sizes: 10×10 Blisters or Bottles of 30 (Optimized specifically for strict, heavily monitored chronic oncology dispensing or monthly fertility cycles).
Ondansitron Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Flash-Dispersion ODT or Standard Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant peelable Alu-Alu blister strips to ensure the absolute chemical stability of the highly hygroscopic ODT matrix.
Active Ingredient Strength Primary Clinical Function Ondansetron (as HCl Dihydrate) Ph.Eur./USP 4 mg (ODT / FCT) Pediatric & PONV Standard: Base therapeutic unit for post-operative nausea, severe pediatric gastroenteritis, and mild emetic triggers. Ondansetron (as HCl Dihydrate) Ph.Eur./USP 8 mg (ODT / FCT) Global Oncology Standard: High-dose adult maintenance therapy for highly emetogenic chemotherapy (CINV) and radiation therapy (RINV). Excipients (ODT Formulation) Mannitol / Crospovidone / Aspartame / Colloidal Silicon Dioxide / Premium Mint Flavoring Lyophilized Matrix / Superdisintegrant / Sweetener / Saliva-Stimulating Flavor (Engineered specifically to draw saliva into the tablet matrix, forcing a violent, sub-5-second structural collapse on the tongue without a bitter aftertaste) *Pack Sizes: 10×10 Peelable Alu-Alu Blisters (Optimized specifically for strict oncology and surgical dispensing regimens).
Pazopanib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered, High-Density Film-Coated Tablet, packed exclusively in highly secure, child-resistant heavy-gauge HDPE bottles or specialized Alu-Alu blister strips to ensure the absolute chemical stability of the cytotoxic molecule and prevent accidental exposure.
Active Ingredient Strength Primary Clinical Function Pazopanib HCl INN/Ph.Eur. 200 mg (Base Equivalent) Dose-Modification Standard: Essential unit for precise dose reduction in patients experiencing severe hepatic toxicity or adverse drug reactions. Pazopanib HCl INN/Ph.Eur. 400 mg (Base Equivalent) Global Clinical Standard: Primary therapeutic unit designed to achieve the massive 800 mg daily protocol with minimal pill burden. Excipients Microcrystalline Cellulose / Sodium Starch Glycolate / Povidone K30 / Magnesium Stearate / Hypromellose / Titanium Dioxide Diluent / Superdisintegrant / Binder / Lubricant / Premium Cytotoxic-Barrier Film-Coating (Engineered specifically to seal the lethal HPAPI inside the tablet, completely protecting healthcare workers and caregivers from highly toxic dust exposure) *Pack Sizes: Bottles of 30 or 60 Tablets (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
